Malabsorption Syndrome Market by Disease Type and Geography - Forecast and Analysis 2022-2026

The malabsorption syndrome market share is expected to increase to USD 1.55 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.73%.

This malabsorption syndrome market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers malabsorption syndrome market segmentation by disease type (lactose intolerance, sprue, and cystic fibrosis) and geography (North America, Europe, Asia, and Rest of World (ROW)). The malabsorption syndrome market report also offers information on several market vendors, including AbbVie Inc., Ache Laboratorios Farmaceuticos SA, Aspen Pharmacare Holdings Ltd., Bausch Health Companies Inc., Baxter International Inc., COSMO PHARMACEUTICALS NV, Ferring B.V., Koninklijke DSM NV, Lannett Co. Inc., Merck and Co. Inc., Novartis AG, Organon and Co., Perrigo Co. Plc, ProThera Biologics Inc., Sanofi, Tillotts Pharma AG, Xspire Pharma LLC, and Pfizer Inc. among others.

What will the Malabsorption Syndrome Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Malabsorption Syndrome Market Size for the Forecast Period and Other Important Statistics

 

Malabsorption Syndrome Market: Key Drivers, Trends, and Challenges

The higher consumption of gluten-containing food is notably driving the malabsorption syndrome market growth, although factors such as shifting preferences towards dairy-free alternatives may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the malabsorption syndrome industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Malabsorption Syndrome Market Driver

The higher consumption of gluten-containing food is one of the key drivers supporting the malabsorption syndrome market growth. Sprue disease is characterized by an increase in gluten deposition in the body due to the high consumption of gluten-containing food. Meanwhile, a significant rise in per capita income in developed and developing economies has increased the consumption of beer among consumers. The growing demand for craft beer has led to an increase in the number of craft breweries globally. Moreover, vendors are experimenting with new processes and ingredients to add new flavors to craft beer. As most beers are produced using barley, hops, and yeast, they contain gluten. Therefore, consumption of gluten-containing beer will trigger an immune response in people with sprue disease, which is driving the market growth.

Key Malabsorption Syndrome Market Trend

Increased prevalence of cystic fibrosis in Europe, North America, and South America is one of the key malabsorption syndrome market trends contributing to the market growth. The recent advancements in the global malabsorption syndrome market, such as cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for cystic fibrosis, which was recently approved by the Food and Drug Administration (FDA), and the development of inhaled antibacterial drugs drive the global malabsorption syndrome market growth. Significantly, scientists and researchers globally are focusing on improving the lives of people by developing new drugs to thin and loosen mucus to reduce breathing difficulty. Such developments are expected to accelerate the growth of the market focus during the forecast period.

Key Malabsorption Syndrome Market Challenge

Shifting preferences towards dairy-free alternatives is one of the key factors hampering the malabsorption syndrome market growth. Primarily, the preferences of consumers are shifting toward dairy-free alternatives. There are various dairy-free alternatives available in the market, such as soy milk, rice milk, almond milk, margarine, coconut oil, and cooking oils. These alternatives are commonly available in an assortment of different flavors, which will increase their adoption among consumers. In addition, several dairy alternatives have various advantages over dairy products, such as having fewer calories, more nutrients, and rich flavors. Thus, these alternatives will hamper the malabsorption syndrome market growth during the forecast period.

This malabsorption syndrome market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global malabsorption syndrome market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the malabsorption syndrome market during the forecast period.

Who are the Major Malabsorption Syndrome Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• AbbVie Inc.
• Ache Laboratorios Farmaceuticos SA
• Aspen Pharmacare Holdings Ltd.
• Bausch Health Companies Inc.
• Baxter International Inc.
• COSMO PHARMACEUTICALS NV
• Ferring B.V.
• Koninklijke DSM NV
• Lannett Co. Inc.
• Merck and Co. Inc.
• Novartis AG
• Organon and Co.
• Perrigo Co. Plc
• ProThera Biologics Inc.
• Sanofi
• Tillotts Pharma AG
• Xspire Pharma LLC
• Pfizer Inc.

 

This statistical study of the malabsorption syndrome market encompasses successful business strategies deployed by the key vendors. The malabsorption syndrome market is fragmented and the vendors are deploying growth strategies such as price, quality, technology, brand identity, and distribution to compete in the market.

Product Insights and News

• AbbVie Inc. - Under the unified segment, the company conducts research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. 
• AbbVie Inc. - The company offers malabsorption syndrome drugs namely Delzicol DR Capsules. 

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The malabsorption syndrome market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Malabsorption Syndrome Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the malabsorption syndrome market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Malabsorption Syndrome Market?

For more insights on the market share of various regions Request for a FREE sample now!

38% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for malabsorption syndrome in North America. Market growth in this region will be slower than the growth of the market in Europe and Asia.

The high consumption of gluten-containing foods and the growing prevalence of celiac diseases will facilitate the malabsorption syndrome market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 had a negative impact on the regional market as most pharmaceutical companies focused on developing COVID-19 vaccines. However, owing to the initiation of vaccination drives, the demand for non-COVID-19 drugs, including malabsorption syndrome drugs, witnessed steady growth in 2021. Thus, the growing prevalence of lactose intolerance and a rise in demand for gluten-free foods will moderate the growth of the malabsorption syndrome market during the forecast period.

What are the Revenue-generating Disease Type Segments in the Malabsorption Syndrome Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The malabsorption syndrome market share growth by the lactose intolerance segment will be significant during the forecast period. Pharma Lactase is a lactase enzyme produced by the fermentation of a selected strain of bacteria that hydrolyses lactose. Lactase is available as an over-the-counter prevention drug for lactose intolerance. Moreover, the growing application of diagnostic tests, such as lactose intolerance test and hydrogen breath test to determine the presence of lactose malabsorption, which is also referred to as maldigestion, is expected to drive the growth of the lactose intolerance segment during the forecast period. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the malabsorption syndrome market size and actionable market insights on post COVID-19 impact on each segment.

 

Malabsorption Syndrome Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 7.73%
Market growth 2022-2026	$ 1.55 billion
Market structure	Fragmented
YoY growth (%)	5.3
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 38%
Key consumer countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	AbbVie Inc., Ache Laboratorios Farmaceuticos SA, Aspen Pharmacare Holdings Ltd., Bausch Health Companies Inc., Baxter International Inc., COSMO PHARMACEUTICALS NV, Ferring B.V., Koninklijke DSM NV, Lannett Co. Inc., Merck and Co. Inc., Novartis AG, Organon and Co., Perrigo Co. Plc, ProThera Biologics Inc., Sanofi, Tillotts Pharma AG, Xspire Pharma LLC, and Pfizer Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Malabsorption Syndrome Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive malabsorption syndrome market growth during the next five years
• Precise estimation of the malabsorption syndrome market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the malabsorption syndrome industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of malabsorption syndrome market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch